Defend with Profend®

Nasal Antiseptic Kit
to reduce bacteria
on the skin that may
cause infections.





60-second application with Profend® nasal antiseptic swabs reduces 99.7% of *Staphylococcus aureus (S. aureus)* at 10 minutes and 99.9% at 12 hours.[1]

PDI®

BE THE DIFFERENCE®

PROFEND PVP-IODINE NASAL ANTISEPTIC SWABS.

*Defend with **Profend** nasal antiseptic kits.*



60 SEC

Apply for just 60 seconds.

15 seconds per swab— up to 2.5x faster than other PVP-Iodine swabs.[2] Use all 4 swabs for one application.

99.9%

Reduces 99.7% of *S. aureus*

in 10 minutes and 99.9% at 12 hours.[1]

For surgery, ICU, and other hospital areas.

Suitable for reducing carriage of *S. aureus* among patients.[3]

A **SIMPLE** INTERVENTION FOR HIGH-RISK PATIENTS DURING HIGH-RISK PERIODS.



Slim, compact design for patient comfort.

96.6% of patients surveyed are comfortable with nasal application of PVP-Iodine.[4]



Preferred by over 90% of clinicians.[5]

Considered faster and more efficient to use than other nasal PVP-Iodine products.

Just snap and swab.

No preparation needed: pre-saturated swabs are easy to apply, with a neat, dry design.



DATA SHOW INFECTION RISKS CAN BE ANYWHERE.

30%

Up to 30% of healthy adults carry *S. aureus* nasally.[6]


85% of *S. aureus* SSIs* come from the patient's own nasal flora.[7]

9x the risk

Nasal colonization increases SSI risk up to 9x.[8]

77% of SSI-related deaths were directly attributable to the SSI.[9]





Patients in ICUs, long-term care and hemodialysis units are at risk.

S. aureus causes 12% of CLABSIs †[10] and 24% of VAPs.‡[11]

SUITABLE FOR IN-PATIENT/AMBULATORY SURGERY AND THE ICU.

99.9%

Easily incorporate into pre-surgical protocol.

Profend nasal antiseptic swabs reduce *S. aureus* immediately and have 99.7% efficacy at 10 minutes and 99.9% at 12 hours.[1]

ICU

Administer to critical care patients per facility protocol.

Helps reduce *S. aureus* on the skin that may cause infections.



✓

Clinician-administered for increased compliance.


No mixing, mess or complicated steps: just use 4 swabs in nose in 60 seconds.

REDUCE BACTERIA TO HELP REDUCE HOSPITAL EXPENSES.

290,000

290,000 SSI events happen per year.[12]


SSIs are 20% of all HAIs[§12], and account for >90,000 readmissions annually.[13]



Surgical site infections can raise average surgical hospital costs by 82%.[14]

SSIs continue to be an expensive burden to hospital budgets.





Bacterial reduction lowers hospital expenses.[15]

Reducing the presence of *S. aureus* among patients has been shown to reduce HAIs, length of stays, and costs.

NASAL DECOLONIZATION IS PART OF A **NEW STANDARD** OF CARE.

CDC ✓

Nasal decolonization with PVP-I is now a CDC core strategy.

Recommended to reduce *S. aureus* in high risk surgeries, critical care and central IV catheter patients.[3]

AORN ✓

Nasal decolonization is recommended in the AORN guidelines.

Recent guidelines describe the importance of nasal and skin decolonization in SSI reduction[16]

Promote antibiotic stewardship efforts.

As a PVP-Iodine antiseptic, **Profend** nasal swabs support your initiatives against antibiotic resistance.[17]



Profend nasal antiseptic swabs are part of a **layered approach** to reduce bacteria that can cause harmful infections.

No single approach can fully eliminate the risk of HAIs. That's why healthcare institutions need multiple layers of defense to attack infections from all angles. **Profend** nasal antiseptic kits can help provide effective bacterial load reduction at the innermost layer: patients themselves. It's just one of PDI Healthcare's integrated products that helps you implement an overall infection prevention strategy.



Learn more at ***www.DefendwithProfend.com***

	NDC	REORDER NO.	COUNT	CASE PACK	TI/HI	CASE WEIGHT	CASE CUBE
Profend® Nasal Antiseptic Kit							
Patient Kit	#10819-3888	X12048	48 patient units/case	4 swabs/patient pack, 12 patient packs/shelf unit, 4 shelf units/case	30/5	2.7 lbs	0.263 ft³

References: 1. PDI Study PDI-0113-CTEV01. **2.** Instructions for use when compared to competitor products. **3.** Centers for Disease Control and Prevention. Strategies to Prevent Hospital-onset Staphylococcus aureus Bloodstream Infections in Acute Care Facilities. https://www.cdc.gov/hai/prevent/staph-prevention-strategies.html. Published December 2019. Accessed December 10, 2020. **4.** Maslow J, Hutzler L, Cuff G, Rosenberg A, Phillips M, Bosco J. Patient experience with mupirocin or povidone-iodine nasal decolonization. *Orthopedics*. 2014;37(6):e576–e581. **5.** PDI user acceptance study. **6.** VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA. Follow-up of *Staphylococcus aureus* nasal carriage after 8 years: redefining the persistent carrier state. *J Clin Microbiol*. 1999;37:3133–3140. **7.** Septimus EJ. Nasal Decolonization: What antimicrobials are more effective prior to surgery? *Am J Infect Control* 2019;47S:A53-A57. doi: 10.1016/j.ajic.2019.02.028. **8.** Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA. Nasal carriage of *Staphylococcus aureus* is a major risk factor for surgical-site infections in orthopedic surgery. *Infect Control Hosp Epidemiol*. 2000;21(15)319-323. **9.** Awad SS. Adherence to surgical care improvement project measures and post-operative surgical site infections. *Surg Infect (Larchmt)*. 2012;13(4):234–237. **10.** Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant *Staphylococcus aureus* central line-associated bloodstream infections in US intensive care units, 1997-2007. *JAMA*. 2009;301(7):727–736. doi:10.1001/jama.2009.153. **11.** Greene LR, Sposato K. Guide to the elimination of ventilator-associated pneumonia. Washington, DC: Association for Professionals in Infection Control and Epidemiology (APIC); 2009. http://www.apic.org/Resource_/EliminationGuideForm/18e326ad-b484-471c-9c35-6822a53ee4a2/File/VAP_09.pdf. Accessed January 23, 2018. **12.** Klevens RM, Edwards JR, Richards CL, et al. Estimating healthcare-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep*. 2007;122(2):160–166. **13.** Ban KA, Minei JP, Laronga C, et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. *J Am Coll Surg*. 2017;224(1):59–74. **14.** Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with *Staphylococcus aureus* surgical site infection. *Clin Infect Dis*. 2003;36(5)5:592–598. **15.** Nelson R, Samore M, Smith K, et al. Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant *Staphylococcus aureus* carriers. *Clin Microbiol Infect*. 2010;16(12):1740–1746. **16.** "Guideline for Preoperative Patient Skin Antisepsis." *AORN Guidelines for Perioperative Practice*, Jan. 2026, pp. 637–690. **17.** Sievert D, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol*. 2013;34(1):1–14.

* Surgical site infections
† Central line-associated bloodstream infections
‡ Ventilator-associated pneumonia
§ Healthcare-associated infections

©2026 PDI UPDATE 1026 PDI01217247

400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677
T: 800.999.6423 W: pdihc.com

PDI®
BE THE DIFFERENCE